Vertex Pharmaceutic Ownership

VRTX
 Stock
  

USD 294.52  2.36  0.81%   

Some institutional investors establish a significant position in stocks such as Vertex Pharmaceutic in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Vertex Pharmaceutic, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Also, please take a look at World Market Map.
  
Vertex Pharmaceutic Total Assets Per Share are fairly stable at the moment as compared to the past year. Vertex Pharmaceutic reported Total Assets Per Share of 52.78 in 2021. Debt to Equity Ratio is likely to rise to 0.05 in 2022, whereas Inventory Turnover is likely to drop 2.81 in 2022.
Vertex Pharmaceutic maintains a total of 254.25 Million outstanding shares. The majority of Vertex Pharmaceutic outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Vertex Pharmaceutic to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Vertex Pharmaceutic. Please pay attention to any change in the institutional holdings of Vertex Pharmaceutic as this could imply that something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Vertex Stock Ownership Analysis

About 94.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 2.54. Vertex Pharmaceutic recorded earning per share (EPS) of 8.34. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 24th of August 2000. Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 00 people. For more information please call Jeffrey Leiden at 617 341-6100 or visit www.vrtx.com.

Vertex Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Vertex Pharmaceutic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vertex Pharmaceutic backward and forwards among themselves. Vertex Pharmaceutic's institutional investor refers to the entity that pools money to purchase Vertex Pharmaceutic's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Blackrock IncCommon Shares25.1 M7.1 B
Vanguard Group IncCommon Shares20.8 M5.9 B
Fmr LlcCommon Shares16.8 M4.7 B
Jpmorgan Chase CoCommon Shares5.2 M1.5 B
Geode Capital Management LlcCommon Shares4.5 M1.3 B
Loomis Sayles Co L PCommon Shares4.5 M1.3 B
Massachusetts Financial Services CoCommon Shares4.3 M1.2 B
Note, although Vertex Pharmaceutic's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Vertex Pharmaceutic Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vertex Pharmaceutic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vertex Pharmaceutic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vertex Pharmaceutic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Vertex Pharmaceutic Investors Sentiment

The influence of Vertex Pharmaceutic's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Vertex. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Vertex Pharmaceutic's public news can be used to forecast risks associated with investment in Vertex. The trend in average sentiment can be used to explain how an investor holding Vertex can time the market purely based on public headlines and social activities around Vertex Pharmaceutic. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Vertex Pharmaceutic's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Vertex Pharmaceutic's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Vertex Pharmaceutic's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Vertex Pharmaceutic.

Vertex Pharmaceutic Implied Volatility

    
  17.11  
Vertex Pharmaceutic's implied volatility exposes the market's sentiment of Vertex Pharmaceutic stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Vertex Pharmaceutic's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Vertex Pharmaceutic stock will not fluctuate a lot when Vertex Pharmaceutic's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vertex Pharmaceutic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vertex Pharmaceutic's short interest history, or implied volatility extrapolated from Vertex Pharmaceutic options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Also, please take a look at World Market Map. Note that the Vertex Pharmaceutic information on this page should be used as a complementary analysis to other Vertex Pharmaceutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.

Complementary Tools for Vertex Stock analysis

When running Vertex Pharmaceutic price analysis, check to measure Vertex Pharmaceutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceutic is operating at the current time. Most of Vertex Pharmaceutic's value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Vertex Pharmaceutic's price. Additionally, you may evaluate how the addition of Vertex Pharmaceutic to your portfolios can decrease your overall portfolio volatility.
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Is Vertex Pharmaceutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceutic. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
11.1
Market Capitalization
75.5 B
Quarterly Revenue Growth YOY
0.23
Return On Assets
0.14
Return On Equity
0.3
The market value of Vertex Pharmaceutic is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceutic's value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceutic's market value can be influenced by many factors that don't directly affect Vertex Pharmaceutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceutic's value and its price as these two are different measures arrived at by different means. Investors typically determine Vertex Pharmaceutic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.